{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:11:58Z","timestamp":1793160718774,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016477","name":"CareDx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016477","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004176","name":"Miltenyi Biotec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jtct.2022.02.021","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T05:10:07Z","timestamp":1646370607000},"page":"342.e1-342.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0706-4843","authenticated-orcid":false,"given":"Audrey M.","family":"Sigmund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7936-7547","authenticated-orcid":false,"given":"Nathan","family":"Denlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1829","authenticated-orcid":false,"given":"David","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amneet","family":"Bajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Brammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-0130","authenticated-orcid":false,"given":"Ayman","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4217-5496","authenticated-orcid":false,"given":"Sam","family":"Penza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4522","authenticated-orcid":false,"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Jaglowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.02.021_bib0001","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.021_bib0002","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.021_bib0003","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.02.021_bib0004","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.02.021_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.02.021_bib0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.02.021_bib0007","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.02.021_bib0008","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.02.021_bib0009","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.02.021_bib0010","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtct.2022.02.021_bib0011","unstructured":"National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology\u2014B-cell lymphomas. Version 5.2021, September 21, 2021."},{"key":"10.1016\/j.jtct.2022.02.021_bib0012","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.02.021_bib0013","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.021_bib0014","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.021_bib0015","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.02.021_bib0016","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3816\/CLML.2010.n.030","article-title":"Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies","volume":"10","author":"Elstrom","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2022.02.021_bib0017","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.021_bib0018","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","article-title":"Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation","volume":"20","author":"Hamadani","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.021_bib0019","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.02.021_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40164-021-00248-9","article-title":"Elevated LDH greater than 400 U\/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort","volume":"10","author":"Rabinovich","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.02.021_bib0021","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3389\/fimmu.2020.01941","article-title":"Automated manufacture of autologous CD19 CAR-T cells for treatment of non-Hodgkin lymphoma","volume":"11","author":"Jackson","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2022.02.021_bib0022","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.02.021_bib0023","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","article-title":"Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy","volume":"111","author":"Figura","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtct.2022.02.021_bib0024","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.021_bib0025","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/s41409-021-01420-9","article-title":"Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors","volume":"56","author":"Mohty","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.021_bib0026","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Ot\u00e1hal","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtct.2022.02.021_bib0027","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.02.021_bib0028","first-page":"S61","article-title":"Tettamanti S, Attianese GM, et al. Improvements in CAR-based immunotherapy combining immunomodulatory doses of lenalidomide for the treatment of chronic lymphocytic leukemia","volume":"22","author":"Bertilaccio","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2022.02.021_bib0029","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.02.021_bib0030","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hon.2667","article-title":"The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"37","author":"Zou","year":"2019","journal-title":"Hematol Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722001208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722001208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:02:42Z","timestamp":1763002962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722001208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666636722001208"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.02.021","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}